Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Tunlametinib by Binjiang Pharma for Metastatic Colorectal Cancer: Likelihood of Approval
Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase III for Metastatic Colorectal Cancer. According to GlobalData,...
Data Insights
Tunlametinib by Binjiang Pharma for Metastatic Colorectal Cancer: Likelihood of Approval
Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...